Your browser doesn't support javascript.
loading
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
Zelniker, Thomas A; Wiviott, Stephen D; Mosenzon, Ofri; Goodrich, Erica L; Jarolim, Petr; Cahn, Avivit; Bhatt, Deepak L; Leiter, Lawrence A; McGuire, Darren K; Wilding, John; Averkov, Oleg; Budaj, Andrzej; Parkhomenko, Alexander; Ray, Kausik K; Gause-Nilsson, Ingrid; Langkilde, Anna Maria; Fredriksson, Martin; Raz, Itamar; Sabatine, Marc S; Morrow, David A.
Afiliación
  • Zelniker TA; Division of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Wiviott SD; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mosenzon O; The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Goodrich EL; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jarolim P; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Cahn A; The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Bhatt DL; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York.
  • Leiter LA; Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • McGuire DK; Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Wilding J; Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
  • Averkov O; Pirogov Russian National Research Medical University, Moscow, Russia.
  • Budaj A; Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland.
  • Parkhomenko A; Institute of Cardiology, Kyiv, Ukraine.
  • Ray KK; Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, United Kingdom.
  • Gause-Nilsson I; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Langkilde AM; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Fredriksson M; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Raz I; The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Sabatine MS; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Morrow DA; Deputy Editor, JAMA Cardiology.
JAMA Cardiol ; 8(5): 503-509, 2023 05 01.
Article en En | MEDLINE | ID: mdl-36857035
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Cardiol Año: 2023 Tipo del documento: Article País de afiliación: Austria
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Cardiol Año: 2023 Tipo del documento: Article País de afiliación: Austria